Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05194540 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT05194540 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 136 participants.
The verdict
NCT05194540, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection by an autoinjector in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).
Interventions
- DRUG Tralokinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2023-06-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05194540
The ClinicalTrials.gov registry entry for NCT05194540 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tralokinumab is the first listed.
NCT05194540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05194540 about?
NCT05194540 is a clinical study titled "Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)". The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection by an autoinjector in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).
What is the current status of trial NCT05194540?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2022-01-13. Estimated completion is 2023-06-21.
What interventions are being tested in trial NCT05194540?
The interventions under investigation include: Tralokinumab (DRUG).
Who is sponsoring clinical trial NCT05194540?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.